Oleclumab
Based on 1 publication(s) in Google Scholar
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.90%
- CAS No.: 1803176-05-7
- 분자량:143.14 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
NT5E/CD73
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Murine, Balb/c, syngeneic CT26 colon carcinoma tumor model[2]
-
Dosage:10 mg/kg
-
Administration:ip; 2 time per week, for 2 weeks
-
Result:Inhibited tumor growth by 50% or greater from study day 7 to study day 16 when compared with isotype control antibody-treated groups.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD73/5'-Nucleotidase Protein, Human (HEK293, His, HY-P70010) can bind Oleclumab. The EC50 for this effect is 3.27 ng/mL. -
Flow Cytometry analysis of A431 cells labelling NT5E/CD73 (red) with Oleclumab (anti-NT5E/CD73) (HY-P99039). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 lambda2 (HY-P990096). Black-Unlabelled control, cells without incubation with primary antibody.
Product Details
-
CAS No. 1803176-05-7
-
Accession P21589
-
Synonyms MEDI9447
-
분자량 143.14 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 lambda2
-
Recommend Isotype Controls
-
Format
-
Human IgG1 lambda
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.90%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
선적
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
순도&문서
References
[1]. Roy S Herbst, et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr 22;JCO2200227. [Content Brief]
[2]. Hay CM, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology. 2016 Jul 11;5(8):e1208875. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)